Literature DB >> 19729056

Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice.

N Mirahmadi1, M H Babaei, A M Vali, S Dadashzadeh.   

Abstract

Peritoneal carcinomatosis is a serious concern when treating digestive or ovarian tumors. Treatment with systemic chemotherapy suffers from poor penetration of cytotoxic agents into the peritoneal cavity and is not quite effective. Local delivery of drugs, especially as controlled-release delivery systems like liposomes, could provide sustained and higher drug levels and reduce systemic toxicity. In order to investigate the effect of liposome size on peritoneal retention, liposomes composed of distearoylphosphatidylcholine and cholesterol (DSPC/CHOL, molar ratio 2:1) were prepared at four sizes of 100, 400, 1000 and 3000 nm. Subsequently, these liposomes were labeled with (99m)Tc complex of hexamethylpropyleneamineoxime ((99m)Tc-HMPAO) and injected into mouse peritoneum. Then, mice were sacrificed at eight different time points and the percentage of injected radiolabel in the peritoneal cavity and the organ distribution in terms of percentage injected dose/gram tissue (%ID/g) were obtained. Results showed that the free label ((99m)Tc-HMPAO) was cleared very rapidly from the cavity so that after 5 min and 7h only 6.89+/-2.51% and 0.91+/-0.51% of the injected dose was recovered, respectively. However, for the liposomal formulations, this recovery value ranged from 8.47+/-1.62% to 29.99+/-12.06% at 7h. Peritoneal retention of the vesicles was increased with their size, and the highest retention rate was obtained with 1000 nm liposomes with an AUC value 15.51 times that of (99m)Tc-HMPAO. In blood, as expected, 100 nm liposomes showed much higher levels because of their greater stability. Their greater blood concentration also caused increased levels in the heart and kidneys, although their organ to blood AUC ratio was the lowest. Overall, among the different sized neutral liposomes investigated, the 1000 nm vesicles seemed to be the most optimal, achieving a greater peritoneal level and retention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729056     DOI: 10.1016/j.ijpharm.2009.08.034

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

1.  Tuning the Size of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles Fabricated by Nanoprecipitation.

Authors:  Wei Huang; Chenming Zhang
Journal:  Biotechnol J       Date:  2017-10-13       Impact factor: 4.677

Review 2.  Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation.

Authors:  Muneeb Ahmed; Marwan Moussa; S Nahum Goldberg
Journal:  Chem Phys Lipids       Date:  2011-12-14       Impact factor: 3.329

Review 3.  Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.

Authors:  Jessie L-S Au; Ze Lu; M Guillaume Wientjes
Journal:  AAPS J       Date:  2015-06-19       Impact factor: 4.009

4.  Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes.

Authors:  Jai Woong Seo; Shengping Qin; Lisa M Mahakian; Katherine D Watson; Azadeh Kheirolomoom; Katherine W Ferrara
Journal:  J Control Release       Date:  2011-01-15       Impact factor: 9.776

5.  Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer.

Authors:  Yu Hang; Siyuan Tang; Weimin Tang; David Větvička; Chuhan Zhang; Ying Xie; Fei Yu; Ao Yu; Diptesh Sil; Jing Li; Rakesh K Singh; David Oupický
Journal:  J Control Release       Date:  2021-03-25       Impact factor: 9.776

6.  Temperature-sensitive gels for intratumoral delivery of β-lapachone: effect of cyclodextrins and ethanol.

Authors:  Marcilio S S Cunha-Filho; Carmen Alvarez-Lorenzo; Ramón Martínez-Pacheco; Mariana Landin
Journal:  ScientificWorldJournal       Date:  2012-04-24

7.  Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination.

Authors:  Susumu Hama; Takayuki Nishi; Eitaro Isono; Shoko Itakura; Yutaka Yoshikawa; Akinori Nishimoto; Satoko Suzuki; Naoko Kirimura; Hiroaki Todo; Kentaro Kogure
Journal:  Cancer Sci       Date:  2022-03-31       Impact factor: 6.518

8.  Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.

Authors:  Siyuan Tang; Yu Hang; Ling Ding; Weimin Tang; Ao Yu; Chuhan Zhang; Diptesh Sil; Ying Xie; David Oupický
Journal:  Mol Pharm       Date:  2021-10-26       Impact factor: 5.364

9.  Noninvasive imaging of radiolabeled exosome-mimetic nanovesicle using (99m)Tc-HMPAO.

Authors:  Do Won Hwang; Hongyoon Choi; Su Chul Jang; Min Young Yoo; Ji Yong Park; Na Eun Choi; Hyun Jeong Oh; Seunggyun Ha; Yun-Sang Lee; Jae Min Jeong; Yong Song Gho; Dong Soo Lee
Journal:  Sci Rep       Date:  2015-10-26       Impact factor: 4.379

10.  Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice.

Authors:  Sara Westrøm; Marion Malenge; Ida Sofie Jorstad; Elisa Napoli; Øyvind S Bruland; Tina B Bønsdorff; Roy H Larsen
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.